Neovision Capital

Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization.

Dakang Medical is a chain of independent blood purification medical service institutions. Dakang Medical is a company whose leading industries are medical investment, medical institution management, and brand operation services.

Xingsai Bio is a developer of single-cell analysis instruments and supporting reagents and consumables.

Maibang Bio provides biomedical process solutions such as R&D and production, customized medium optimization and development services, and liquid medium production. Their cell-culture medium companies might benefit from product performance and optimization development services. Maibang Bio focuses on the development and production of high-end chemically defined media products, the optimized development of customized media services, large-scale dry powder/liquid medium production, and other comprehensive biomedical process solutions.

Nuoyuan Medical specializes in precision tumor surgery and treatment technology.

RzonTech is a provider of industrial software products, data services, and overall solutions.

Matrixtime is an AI technology start-up. Based on deep learning, it is committed to the development of complex machine vision and industrial robot AI system products, empowering high-end manufacturing and providing scene-oriented industrial AI products. From high-end semiconductor manufacturing into complex machine vision inspection, Matrixtime has covered scenarios including advanced semiconductor manufacturing, photovoltaic energy, automotive precision manufacturing, and unmanned ports.

Xgene Pharmaceutical is a late-clinical stage, venture-backed international company that uses proprietary linker technology to develop novel, multimodal conjugated molecules for the treatment of neurological disorders. Current programs are aimed at increasing the efficacy and tolerability of pain medications.

Chineo is a CAR-T immune cell therapy service provider.

Andisec focuses on the research and development of industrial network security technology, products, and services.

Rimag is a Shenzhen-based medical imaging service provider. They are specialized in medical imaging center operation, relevant cloud technology development, and talent training.

Hualan New Materials is a bio-pharma firm focusing on the production of direct or indirect contact injection pharma packaging materials.

Shenzhen MicroApproach Medical Technology Co., Ltd., found in September 2015 with a registered capital of 30 million yuan, is mainly committed to research, manufacture and merchandize of endovascular medical devices.Their company is a high-tech enterprise in the novel industry of intravascular intervention medical devices, focusing on the development and application of proprietary intellectual rights. Thus, the Shenzhen Science and Technology Innovation Committee awarded their company with a title of “Engineering Technology Center of Endovascular Medical Devices”. Their company has a strong capacity for research and development, and established a close scientific research collaboration with Beijing Tiantan Hospital, the People's Liberation Army 301 Hospital, Wuhan Tongji Hospital, China Medical University, Shenzhen People's Hospital and other well-known large scientific research institutes. They have also established a first-class R&D group, covering various fields, including neurosurgery，polymer materials, biomedical engineering, immunology and so on. Their company has always followed the tenet "Quality First & Respect for Life," and served the purpose of "Innovation, Enterprise, Pragmatism, Cooperation and Win-Win" in their company culture. Furthermore, they are committed to provide first-class intravascular intervention products for the majority of medical professionals and patients, and make a contribution for domestic development of endovascular intervention medical devices in China. In order to achieve a large-scale production and standardized management, their company has established a sound management system for medical devices production, and built a state of the art industrial production line for hydrophilic coating guide wire.

Hocermed is a provider of energy platforms for invasive surgery. They has established research and development bases. They creates a comprehensive system that supports research and development, quality control, production, sales, and service. They supplies products with minimally invasive surgical solutions to healthcare professionals. They also invasive surgical energy devices. They provides surgical products and services to surgeons.

PROPRIUM creates biomedical products and diagnostic techniques intended to serve the biotech field. The company has diagnostic techniques to detect carcinoma, liver, cardiovascular, and cerebrovascular diseases. They offer cancer diagnostics, genetic testing, elisa, lateral flow assays, and personalized medicine.

Allist Pharmaceuticals is a pharmaceutical enterprise that discovers, develops, and commercializes innovative medicines. Allist Pharmaceuticals is oriented by unmet clinical demands in the global pharmaceutical market, with a special focus on tumor treatment, under the development concept of advancing long life through scientific and technological innovation. Allist Pharmaceuticals develops medicines with the commitment to creating safe, effective, and inclusive innovative drugs with independent intellectual property rights.

Founded in 2004, Smartee is a leading provider of digital invisible orthodontic solutions in China. As of March 2022, Smartee’s 23.6 million sets of clear aligners have successfully served orthodontic consumers worldwide. Smartee is headquartered in Shanghai, China, and overseas headquarters were established in the UK in 2021. Smartee’s production and R&D base are in Jiaxing Science and Technology City. Smartee currently has over 1,700 employees including a medical team of over 380 members led by professional PhD Orthodontists working in the Smartee Invisible Orthodontic Clinical Medical Center. Our large scale automated intelligent production base in China's "Dental Valley" (Ziyang, Sichuan) serves domestic China and the global market. As one of the leading brands in China’s invisible orthodontics industry, Smartee has introduced 3D printing technology into the field of stomatology instruments production in China and for the first time realized the large-scale production of customized clear aligners. "Innovation" is in the DNA of Smartee. Smartee bracketless invisible orthodontic technology combines clinical stomatology, computer science, biomechanics, 3D printing, and polymer material science, and has achieved a total of over 500 patents since March 2022. Smartee has a database of over 520,000 orthodontic cases, which is growing at a rate of more than 100% per year. It is recognized as one of the most innovative and growing high-tech companies in the field of stomatology R&D and production in China. Smartee's efforts and contributions in promoting the development of the Chinese invisible orthodontic industry have been fully recognized and accepted by all sectors of the industry. It is a member of the 3D Printing Medical Devices Committee of the China Association for Medical Devices Industry, a member of the team that jointly drafted the Chinese oral digitalization wording standard，a standing committee member of the Chinese Stomatological Association, an executive director unit of the Shanghai Medical Instrument Trade Association, and has obtained various honorary titles such as National Hightech Enterprise and Shanghai Little Giant Enterprise. In 2015, KaVo Group, the world's leading manufacturer of dental equipment and consumables, became a shareholder of Smartee, which announced that KaVo Group had made a strategic layout for the promising field of invisible orthodontics. In 2018, Smartee began working with the world-famous University of North Carolina (UNC) School of Dentistry to jointly research and develop orthodontic clinical medicines and clear aligners related to biomechanics and medical polymer materials. In 2019, Smartee officially became a strategic cooperative partner of China Aerospace. The two would fully combine their respective technological and resource advantages and launch a series of strategic cooperations. Smartee joined hands with China Aerospace to advance the development of China's orthodontic industry. Meanwhile, Smartee worked together with the orthodontic team led by Professor Shen Gang to develop Smartee S8 S9 S10 mandibular repositioning invisible orthodontic solutions. Smartee also completed series C funding in the same year. Investors include well known domestic and foreign industry funds and investment agencies in the medical field with solid financial strength. In 2020, Smartee cooperated with the orthodontic team led by Professor Shen Gang for the second time to develop S11 alveolar orthopaedic technology, and for the third time to start the research and development of S12 invisible and fixed fusion orthodontic technology, S16 Invisible forward traction technology. In the same year, Smartee launched a series of innovative products and technology such as multi-layer sheets and S15 Smartee Hook traction technology. In 2021, Smartee continued its cooperation with Professor Shen Gang to develop S17, S18, S19, the mandibular maintenance and perioperative orthodontic solutions. In 2022, Smartee was officially authorized to use Disney and Marvel IPs for its new Smartee Teen products for children and teenagers. With the launching of Smartee Teen, Smartee has been able to provide consumers of all ages with orthodontic correction management. In March 2022, Smartee closed its series D funding round of US$ 80 million. This round of financing will continue to accelerate its expansion in the global orthodontic industry. In the future, guided by brand and driven by innovation and capital, Smartee will adhere to the medical essence of invisible orthodontics and provide safe, efficient, and comfortable invisible orthodontic products and services to global consumers and doctors, and make healthy and beautiful smiles predictable.

Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.

Rimag is a Shenzhen-based medical imaging service provider. They are specialized in medical imaging center operation, relevant cloud technology development, and talent training.

Automobile insurance sales management platform.

PANDAINS is an automobile insurance platform.

PANDAINS is an automobile insurance platform.

ACROBiosystems develops recombinant antigens for emergency SARS-CoV-2 variants. They also produce a series of GMP-grade cytokines under the GMP-quality management system. Their products include fc receptor proteins, immune checkpoint proteins, llama IgG fc fusion proteins, biomarkers, CD antigens, and more.

Oranger is a developer of portable wearable medical devices, focused on the treatment of medical-grade chronic respiratory diseases such as sleep apnea.

Shanghai Genext Pharmaceutical Technology Co., Ltd operates in the transplant industry in the People’s Republic of China. It offers transplantation drugs and instruments, in-vitro diagnostics, and production bases of medical devices. The company offers TDx, organ preservation and immune function platform, immunosuppressant, and therapeutic drug monitoring equipment, as well as operation accessories. It encompasses various hospital transplants, which include kidney transplant, heart transplant, lung transplant, bone marrow transplant, cell transplant, etc. The company was formerly known as Shanghai Genext Pharmaceutical Technology Ltd. Shanghai Genext Pharmaceutical Technology Co., Ltd was founded in 2003 and is headquartered in Shanghai, the People’s Republic of China.

Boke Information Co., Ltd. is engaged in the research and development of management software, and providing management consultancy services in China. It also provides implementation and technology services relevant to management software products for various enterprises, government, and community organizations in China. It originally creates personalized products with the idea of autonomous configuration, self-expansion, and autonomous maintenance. It makes an IT deployment according to the whole life cycle for enterprises to help clients to build ecological organization chart and the whole lifecycle system framework.

Founded in April 2014, Renren is the first to enter the used car market in C2C mode. It has developed into a comprehensive car trading service platform integrating used cars and new car transactions, financial services and after-sales services. For second-hand car transactions, Renren provides free door-to-door valuation, sales, replacement and other services for the majority of car owners. In order to strictly control the quality of the car in the sale, the Renren car has established a 249 test standards and a dual detection mechanism through a self-built professional appraisers team, and has reached a cooperation with the China Automobile Dealers Association to become a national standard for second-hand car testing. The industry's first strategic partner in the “certification” certification, the layer of protection is only for the rest of the car. At the same time, for the buyer, the Renren car provides a series of after-sales guarantees such as 14-day returnable car, one-year/20,000-kilometer core component warranty and 200 million yuan guarantee, leading the industry change. In April 2018, Renren was awarded a new round of financing by the Goldman Sachs Group, Tencent, Didi and other investments of $300 million. This is the third time that Tencent has added a Renren car. Previously, Renren had won a strategic investment of 200 million US dollars, and then carried out in-depth cooperation in ecological co-construction, technology, and operation.